Clinical trial results and regulatory update
On 9 – 13 May 2007, Intercytex presented a poster at the
68th Annual meeting of the Society of Investigative Dermatology in
Los Angeles, California.
www.sidnet.org
To see the poster in a downloadable format, please click on the link below:
For further details please click on the following link to read the press release.
On 10 March 2006, VAVELTA®'s regulatory status was confirmed by the MHRA as a tissue engineered product under the EU Directive but that pending its implementation, the supply of VAVELTA® would not be subject to licensing.
For further details please click on the following link to read the press release.
